Lupin Ltd informs demise of Dr. Sofia Mumtaz on August 17, 2026

0 min read Updated on 18 Aug 2026, 10:18 PM

Reviewed by

Ashish TScanX News Team

AI Summary

Lupin Limited announced the death of Dr. Sofia Mumtaz, President of Legal & Compliance for Canada, ANZ & NEA Business, on August 17, 2026. The disclosure was filed with NSE and BSE under Regulation 30 of the SEBI Listing Regulations. Dr. Mumtaz passed away in the U.S.A.

*this image is generated using AI for illustrative purposes only.

Lupin Limited has informed the stock exchanges of the demise of Dr. Sofia Mumtaz, who served as President, Legal & Compliance for the Canada, ANZ & NEA Business segment. The senior management personnel passed away on August 17, 2026, in the U.S.A.

The pharmaceutical company made the disclosure pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references the SEBI Master Circular dated January 30, 2026.

Key Details

The specific details regarding the cessation of service are outlined below:

Particulars	Details
Name:	Dr. Sofia Mumtaz
Designation:	President, Legal & Compliance, Canada, ANZ & NEA Business
Reason for Change:	Demise
Date of Cessation:	August 17, 2026
Location:	U.S.A.

Amit Kumar Gupta, Company Secretary & Compliance Officer, signed the communication addressed to the National Stock Exchange of India Limited and BSE Limited. The registered office of Lupin Limited is located in Mumbai.

Historical Stock Returns for Lupin

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.20%	-2.96%	-8.64%	-0.69%	+13.40%	+129.08%

How will Lupin Limited plan to restructure the Legal & Compliance leadership for the Canada, ANZ, and NEA regions following Dr. Mumtaz's passing?

What impact might this leadership vacancy have on Lupin's ongoing regulatory submissions or compliance audits in North America and the Asia-Pacific markets?

Will Lupin initiate a search for an internal successor or look to external candidates to fill the President, Legal & Compliance role?

Read Next Article

Lupin secures US FDA approval for generic Pitolisant Tablets

1 min read Updated on 17 Aug 2026, 12:34 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Lupin received final US FDA approval for its ANDA for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths, approved as bioequivalent to Wakix®. The disclosure was made under Regulation 30 of SEBI's LODR Regulations, 2015. The approval strengthens Lupin's US generics pipeline in the central nervous system therapy area, complementing its 15 manufacturing sites and six research centers globally.

*this image is generated using AI for illustrative purposes only.

Lupin Limited received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Pitolisant Tablets in strengths of 4.45 mg and 17.8 mg. The approval designates the product as bioequivalent to the reference listed drug Wakix®, clearing the path for a US market launch of the generic version.

Approval details

The key parameters of the regulatory approval are as follows:

Parameter:	Details
Drug:	Pitolisant Tablets
Strengths:	4.45 mg and 17.8 mg
Reference drug:	Wakix®
Approval type:	Final ANDA approval
Regulator:	US FDA

Regulatory context

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company issued the press release to the National Stock Exchange of India Limited and BSE Limited on August 17, 2026.

Portfolio implications

Pitolisant is used in the treatment of central nervous system disorders. By securing approval for these specific strengths, Lupin adds another branded-equivalent product to its US generics pipeline. The company operates 15 manufacturing sites and six research centers globally, supporting its focus on complex generics and specialty formulations across therapy areas including respiratory, cardiovascular, and central nervous system health.

Historical Stock Returns for Lupin

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.20%	-2.96%	-8.64%	-0.69%	+13.40%	+129.08%

How is Lupin planning to differentiate its pricing strategy for generic Pitolisant against the branded reference drug Wakix® in the US market?

What is the projected timeline for Lupin to achieve significant market share penetration given the existing competition in the central nervous system generics segment?

Could this FDA approval serve as a catalyst for Lupin to accelerate the submission of other complex CNS formulations currently in its pipeline?